More than one million patients have been diagnosed with CRC per year, and the mortality of CRC is the third amongst all cancers.1 Metastasis is responsible for cancer poor prognosis, and epithelial‐to‐mesenchymal transition (EMT) is a significant program at the beginning of cancer metastasis.2, 3, 4 EMT is activated by several pathways, such as MAPK/ERK1/2, PI3K/AKT, FAK/Src, WNT/β‐catenin and TGF‐β/Smad pathways.5 The gene discussed is MAPK3; the disease is cancer.